Perspective Therapeutics Q2 EPS Increased by HC Wainwright

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – HC Wainwright raised their Q2 2026 EPS estimates for Perspective Therapeutics in a report issued on Monday, June 1st. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.23) for the quarter, up from their prior estimate of ($0.25). HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($0.96) EPS.

Other analysts also recently issued reports about the company. BTIG Research reiterated a “buy” rating and set a $14.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, March 17th. B. Riley Financial boosted their price target on Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Truist Financial set a $12.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. UBS Group boosted their target price on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Finally, Royal Bank Of Canada reduced their price target on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and a consensus price target of $12.63.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN:CATX opened at $3.60 on Wednesday. The business’s 50 day simple moving average is $4.13 and its 200 day simple moving average is $3.72. Perspective Therapeutics has a 1 year low of $1.96 and a 1 year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million.

Hedge Funds Weigh In On Perspective Therapeutics

Several large investors have recently bought and sold shares of the company. Commodore Capital LP bought a new stake in shares of Perspective Therapeutics during the first quarter worth about $26,424,000. Avidity Partners Management LP grew its holdings in Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after acquiring an additional 2,839,266 shares during the last quarter. Vanguard Group Inc. increased its position in Perspective Therapeutics by 5.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock valued at $11,792,000 after acquiring an additional 163,532 shares during the period. Affinity Asset Advisors LLC raised its stake in shares of Perspective Therapeutics by 954.9% during the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after acquiring an additional 2,864,582 shares during the last quarter. Finally, Spruce Street Capital LP acquired a new position in shares of Perspective Therapeutics during the first quarter worth $10,955,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.